Lenalidomide for the treatment of mantle cell lymphoma

References

• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26–38.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma prognostic factors project. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87(10):4302–4310.
   PubMed Web of Science ®Google Scholar
• Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105(11):4445–4454.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Tumor cell proliferation (Ki-67 index) overcomes cytology and growth pattern as prognostic factor inmantle-cell lymphoma–results from randomized trials of the European MCL Network. Blood 2014;124. Abstract 2977. (ASH proceedings).Hoster E, Rosenwald A, Berger F, et al. Tumor cell proliferation (Ki-67 index) overcomes cytology and growth pattern as prognostic factor inmantle-cell lymphoma–results from randomized trials of the European MCL Network. Blood 2014;124. Abstract 2977. (ASH proceedings).
   Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530–1533.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34:1386–1394.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue M-H, Klapper W, Berger F, et al. European mantle cell lymphoma network. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604–611.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol. 2016;34:1256–1269.
   PubMed Web of Science ®Google Scholar
• Rummel M, Atta J, Welslau M. Bendamustine and rituximab (BR) are effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Pomponi F, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle cell non-Hodgkin lymphoma ineliglible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in pateints with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-toevent analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell lymphoma. Blood. 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Inwards DJ, Rowland KM, et al. low-dose single-agenttemsirolimus for relapsed mantle cell lymphoma: A phase 2 trial inthe North central cancer treatment group. Cancer. 2008;113:508–514.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluatetemsirolimus compared with investigator’s choice therapy forthe treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Wang L, Rule S, Martin P, et al. Targeting BTK with Ibruitinib inrelapsed or refractory mantle cell lymphoma. N Engl J Med. 2014;369:507–516.
   Web of Science ®Google Scholar
• Kahl B, Spurgeon S, Furman RI, et al. Significant clinical activity of CAL-101, an isoform selective inhibitor of phosphatidylinositol 3kinase P110D, in patients with relapsed or refractory indolent andmantle cell lymphoma. Blood. 2014;123:3398–3405.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–667.
   PubMed Web of Science ®Google Scholar
• Li CJ, Jiang C, Liu Y, et al. Pleiotropic action of novel bruton’s tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther. 2018 Nov 9. pii: molcanther.0478.2018. DOI:10.1158/1535-7163.MCT-18-0478.
   Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non- Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.
   PubMed Web of Science ®Google Scholar
• Tam CS, Roberts AW, Anderson M, et al. Combination ibrutinib (IBR) and venetoclax (VEN) for the treatment of mantle cell lymphoma (MCL): primary endpoint assessment of the phase 2 AIM study. Hematol Oncol. 2017;35:144–145.
   Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–1223.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Carreras J, Zhang M, et al. Outcome of patients with mantle cell lymphoma undergoing autologous versus reducedintensity allogeneic transplantation. J Clin Oncol. 2013;49:2454–2460.
   Google Scholar
• Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113:4144–4152.
   PubMed Web of Science ®Google Scholar
• Celgene. Revlimid: Highlights of Prescribing Information Reference ID. 3319577. 2013.
   Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab- treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
   PubMed Web of Science ®Google Scholar
• Mitsiades N. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–4530.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-cell non-hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811.
   PubMed Web of Science ®Google Scholar
• Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126:2366–2369.
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553–559.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–386.
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 2002;168:4914–4919.
   PubMed Web of Science ®Google Scholar
• Hagner PR, Chiu H, Ortiz M, et al. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. Br J Haematol. 2017;179:399–409.
   PubMed Web of Science ®Google Scholar
• Desai M, Newberry KJ, Romaguera J, et al. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013;6:55.
   PubMed Web of Science ®Google Scholar
• Lenalidomide prescribing information. Summit, NJ: Celgene corporation; 2010. Available from 2010 Dec 13: http://www.revlimid.com/pdf/REVLIMID_PI.pdf
   Google Scholar
• Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012;69(3):789‑97.
   Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on dialysis. J Clin Pharmacol. 2007;47:1466–1475.
   PubMed Web of Science ®Google Scholar
• Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2014;2152–2650.Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2014;15(4):2152–2650.
   Web of Science ®Google Scholar
• Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90:429–439.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26:1667–1677.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344–349.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single- agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL- 001(EMERGE) pivotal trial. Br J Haematol. 2015;170:496–503.
   PubMed Web of Science ®Google Scholar
• Trněný M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–331.
   PubMed Web of Science ®Google Scholar
• Stefoni V, Pellegrini C, Gandolfi L, et al. Lenalidomide in pretreated mantle cell lymphoma patients: an Italian observational multicenter retrospective study in daily clinical practice, the Lenamant study. Blood 2015;126. Abstract 3946. (ASH proceedings).
   Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892–2897.
   PubMed Web of Science ®Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Impact of prior treatment on PFS for relapsed/refractory mantle cell lymphoma patients randomized to lenalidomide vs investigator’s choice: a subgroup analysis of the phase II MCL-002 (SPRINT) study. Haematologica 2015;100. Abstract 4. (EHA Meeting Proceedings).
   Web of Science ®Google Scholar
• Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017;102:e203.
   PubMed Web of Science ®Google Scholar
• Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10:171.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–1844.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–e182.
   PubMed Web of Science ®Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol. 2014;166(1):98–108.
   PubMed Web of Science ®Google Scholar
• Rossi D, Ferrero S, Bruscaggin A, et al. A molecular model for the prediction of progression free survival in young mantle cell lymphoma patients treated with cytarabine-based high dose sequential chemotherapy and autologous stem cell transplantation: results from the MCL0208 Phase III trial from fondazione italiana linfomi (FIL). Blood. 2015;126(23):336.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica. 2018.Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica. 2018;103(11):e541–e543. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168:765–768.
   PubMed Web of Science ®Google Scholar
• Axelrod M, Ou Z, Brett LK, et al. Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014;28:407–410.
   PubMed Web of Science ®Google Scholar
• Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017;130(17):1881–1888.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–549.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803–1813.
   PubMed Web of Science ®Google Scholar